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ABSTRACT A new human coronavirus (hCoV-EMC) has emerged very recently in theMiddle East. The clinical presentation re-
sembled that of the severe acute respiratory syndrome (SARS) as encountered during the epidemic in 2002/2003. In both cases,
acute renal failure was observed in humans. HCoV-EMC is a member of the same virus genus as SARS-CoV but constitutes a
sister species. Here we investigated whether it might utilize angiotensin-converting enzyme 2 (ACE2), the SARS-CoV receptor.
Knowledge of the receptor is highly critical because the restriction of the SARS receptor to deep compartments of the human
respiratory tract limited the spread of SARS. In baby hamster kidney (BHK) cells, lentiviral transduction of human ACE2
(hACE2) conferred permissiveness and replication for SARS-CoV but not for hCoV-EMC.Monkey and human kidney cells
(LLC-MK2, Vero, and 769-P) and swine kidney cells were permissive for both viruses, but only SARS-CoV infection could be
blocked by anti-hACE2 antibody and could be neutralized by preincubation of virus with soluble ACE2. Our data show that
ACE2 is neither necessary nor sufficient for hCoV-EMC replication. Moreover, hCoV-EMC, but not SARS-CoV, replicated in cell
lines from Rousettus, Rhinolophus, Pipistrellus, Myotis, and Carollia bats, representing four major chiropteran families from
both suborders. As human CoV normally cannot replicate in bat cells from different families, this suggests that hCoV-EMC
might use a receptor molecule that is conserved in bats, pigs, and humans, implicating a low barrier against cross-host transmis-
sion.
IMPORTANCE A new human coronavirus (hCoV) emerged recently in the Middle East. The disease resembled SARS (severe acute
respiratory syndrome), causing a fatal epidemic in 2002/2003. Coronaviruses have a reservoir in bats and because this novel vi-
rus is related to SARS-CoV, we investigated whether it might replicate in bat cells and use the same receptor (angiotensin-
converting enzyme 2 [ACE2]). This knowledge is highly critical, because the SARS-CoV receptor influenced pathology, and its
localization in the deep respiratory tract is thought to have restricted the transmissibility of SARS. Our data show that hCoV-
EMC does not need the SARS-CoV receptor to infect human cells. Moreover, the virus is capable of infecting human, pig, and bat
cells. This is remarkable, as human CoVs normally cannot replicate in bat cells as a consequence of host adaptation. Our results
implicate that the new virus might use a receptor that is conserved between bats, pigs and humans suggesting a low barrier
against cross-host transmission.
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Coronaviruses (CoVs) are large enveloped plus-strand RNA vi-ruses. Over the last decades, several animal CoVs have been
identified, includingmajor pathogens such as the bovine CoV and
the avian infectious bronchitis virus. Two human CoVs (hCoVs)
termed hCoV-OC43 and hCoV-229E have been known since the
1960s, causing mild respiratory disease (1). In 2002/2003, an out-
break of severe acute respiratory syndrome (SARS) leading to over
700 deaths was caused by a novel hCoV termed SARS-CoV (2, 3).
In the aftermath of the SARS epidemic, two additional hCoVs
termed hCoV-NL63 and -HKU1 as well as numerous novel bat-
associatedCoVswere described (4–7). CoVs have been reclassified
into four genera designated Alphacoronavirus (former groups 1a
and 1b), Betacoronavirus (groups 2a to 2d), Gammacoronavirus
(group 3), and as recently suggested,Deltacoronavirus (8). A likely
animal reservoir for SARS-CoV has been identified in bats (7,
9–11). Nevertheless, bat-derived CoVs have never been isolated in
cell culture. Prototypic CoVs, including the SARS-CoV, are al-
most unculturable in bat-derived cell lines (11, 12). Double infec-
tions of bats with different CoVs are very rare (13), and bat CoVs
appear to be restricted to their bat hosts at the genus level (14, 15).
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These points taken together suggest that there is a tight barrier
against CoV host switching, preventing humans from acquiring
novel CoVs easily (1, 11).
The SARS-CoV utilizes the angiotensin-converting enzyme 2
(ACE2) as its necessary and sufficient cellular receptor (11, 16).
The cellular and anatomic localization of ACE2 in the human
body had an important meaning for the pathogenesis and epide-
miology of SARS. The receptor is expressed on pneumocytes deep
in the human lung, but hardly in the upper parts of the respiratory
tract (17). The direct targeting of pneumocytes may explain why
SARS-CoV infection led to a severe clinical picture with early on-
set of respiratory distress in affected patients. The focusing of
SARS-CoV replication to the deep respiratory tract also deter-
mined a major hallmark of SARS epidemiology. Because the virus
needed to reach the deep respiratory tract to seed an infection, the
infectious dose was rather high. Once infected, primary replica-
tion in the deep lung rapidly caused severe clinical symptoms lead-
ing to early hospitalization and thus, isolation, before patients
could develop high virus concentrations in respiratory secretions.
These factors taken together are thought to have limited the
spread of SARS-CoV in the human population.
In September 2012, health authorities were notified of cases of
severe hCoV infection caused by a novel virus type in the Middle
East region (18, 19). The disease involved severe acute respiratory
failure but as an additional component affected the kidneys, caus-
ing acute renal failure (18, 19). A novel betacoronavirus was iso-
lated from one of two patients in Jeddah, Saudi Arabia, and
termed hCoV-EMC (also named hCoV-EMC/2012) (10, 20). An-
other case originating from Qatar was transferred to London,
United Kingdom, for treatment (18, 19). Very recently, a third
case was reported from Riyadh, Saudi Arabia, suggesting that
more cases are to be expected (21). Availability of a virus isolate
enables rapid provisional assessments of virus properties in order
to guess at virus origins and project epidemic risks. Because of the
taxonomic placement of hCoV-EMC and SARS-CoV as sister
clades within the same virus genus, we were interested in rapidly
assessing any possible overlaps in receptor usage (18, 20).
For the purpose of receptor usage studies, we have established
a baby hamster kidney (BHK) cell line carrying human ACE2
(hACE2) following lentiviral transduction. BHK cells normally do
not express ACE2 and are not permissive for SARS-CoV. As
shown in Fig. 1A, the transduced cells termed BHK-hACE2 ex-
pressed hACE2 as demonstrable by antigen staining using an im-
munofluorescence assay (IFA). Surface expression of hACE2 was
detected by fluorescence-activated cell sorting (FACS). SARS-
CoV applied at a multiplicity of infection (MOI) of 0.5 replicated
more than 10,000-fold within 40 h in BHK-hACE2 but not in the
parental BHK cell line (Fig. 1B). Infectionwith hCoV-EMCunder
the same conditions showed no replication irrespective of the
presence of hACE2. We concluded that hACE2 was sufficient to
permit infection by SARS-CoV, but not hCoV-EMC, inBHKcells.
To exclude technical confounders due to transgenic expression
of hACE2, infection studies were repeated in kidney cells naturally
permissive for SARS-CoV. Next to Vero cells in which the original
isolate of hCoV-EMC had been obtained, LLC-MK2 and MA104
cells are commonly used monkey kidney cell lines known to be
permissive for SARS-CoV (22). As shown in Fig. 1A, LLC-MK2
and MA104 cells expressed ACE2 as demonstrated by IFA and
FACS. SARS-CoV infected cells under conditions as described
above replicated more than 1,000-fold within 40 h in both cell
lines. In contrast, while hCoV-EMC showed strong replication in
LLC-MK2 cells, it did not replicate at all in MA104 cells.
While these findings confirmed that ACE2 did not suffice for
hCoV-EMC permissibility, it might still be necessary in addition
to another receptor. To clarify its usage by hCoV-EMC in primate
cells like LLC-MK2 and Vero cells, a polyclonal goat serum di-
rected against hACE2 was used for receptor-blocking studies. As
shown in Fig. 1C, infection of Vero cells by SARS-CoV, but not
hCoV-EMC, was completely blocked by the antibody. The block-
ing of SARS-CoV infection occurred in a dose-dependentmanner
(see Fig. S1 in the supplemental material).
To exclude the remaining possibility that our antibody blocked
an ACE2 epitope relevant for binding of SARS-CoV but irrelevant
for hCoV-EMC, infection neutralization assays were carried out
using soluble ACE2 protein in Vero cells. As shown in Fig. 1D,
infection with SARS-CoV, but not with hCoV-EMC, could be
competed in a dose-dependent manner by the presence of soluble
ACE2. Overall, these observations led us to conclude that SARS-
CoV, but not hCoV-EMC, utilizes hACE2 as a receptor for virus
entry.
While it is known that SARS-relatedCoVs occurwidely in bats,
the human SARS-CoV is adapted to the human ACE2 receptor
and has lost its ability to infect bat cells (11, 12). For reference, we
generated kidney cells from Rousettus aegyptiacus bats, termed
RoNi/7. As shown in Fig. 2A, lentiviral transduction and selection
yielded a variant of these cells, termed RoNi/7-hACE2, which ex-
pressed hACE2. Infection of these cells with SARS-CoV resulted in
high levels of virus replication, while the parental RoNi/7 cells
were not susceptible (Fig. 2B; see Fig. S2 in the supplemental ma-
terial). Surprisingly, these same parental RoNi/7 cells were highly
permissive for hCoV-EMC. The derived RoNi/7-hACE2 cells ap-
peared slightly more permissive for hCoV-EMC, but by perform-
ing antibody competition experiments, the possibility that this
difference was due to the presence of hACE2 in RoNi/7-hACE2
cells was excluded, as SARS-CoV infection was blocked by anti-
hACE2 antibody, and hCoV-EMC infection was not (Fig. 2C).
The ability of hCoV-EMC to grow in bat cells was highly re-
markable, as most other prototype coronaviruses, including the
human viruses and bovine, feline, or porcine CoVs, are normally
unable to grow in bat cells (9, 12; our unpublished observations).
Because hCoV-EMC was most closely related to bat CoV HKU5
detected in bats of the genus Pipistrellus (18, 20, 23), we generated
two different kidney cell lines from the European bat species Pip-
istrellus pipistrellus as well as a kidney cell line from another Euro-
pean vespertilionid bat species,Myotis daubentonii (MyDauNi/2).
A New World bat cell line from the species Carollia perspicillata
(CarNi/1) was made, and a permanent cell line from Rhinolophus
landeri lung cells was included to represent the bat genus associ-
ated with SARS-related CoV. Porcine kidney cells (PS) were tested
to represent a larger range of laurasiatherian mammals, and a
human kidney cancer cell line (769-P) was included to comple-
ment the tested range of primate cells. As shown in Fig. 2B, all of
the bat cell lines were readily infected by hCoV-EMC (lower
panel) but not by SARS-CoV (upper panel). Porcine and human
kidney cell lines were infected by both coronaviruses (Fig. 2B). In
summary, hCoV-EMC was able to infect cells from four major
families of bats covering the whole diversity of this large mamma-
lian order (Pteropodidae [Rousettus], Rhinolophidae [Rhinolo-
phus], Vespertilionidae [Pipistrellus, Myotis], Phyllostomidae
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FIG 1 Human ACE2-independent entry of hCoV-EMC. (A) Baby hamster kidney (BHK) cells were transduced with hACE2-carrying lentiviruses and selected
by puromycin treatment. (Left) hACE2 expression was controlled by immunofluorescence assay (IFA) by using goat anti-hACE2 immunoglobulin (Ig) (R&D
Systems) followed by cyanin 3-labeled donkey anti-goat Ig (Dianova). For controls, ACE2-expressing primate cell lines (kidney cells from rhesus monkey
[LLC-MK2] and African green monkey [MA104]) were stained in parallel. DAPI, 4’,6’-diamidino-2-phenylindole. Bar, 50 m. (Right) ACE2 protein surface
expression was determined by FACS analysis using a mouse anti-hACE2 Ig antibody (R&D Systems) in combination with an Alexa Fluor 647-labeled goat
anti-mouse Ig (Life Technologies). Data were acquired using FACS Canto and analyzed with FlowJo software. The cells were incubated with the secondary
antibody only (shown in gray) for a control. mAB,monoclonal antibody. (B) The interferon-deficient BHK cells and the generated hACE2-expressing transgenic
BHK cells were applied in infection studies. LLC-MK2 andMA104 primate cells known to be susceptible for SARS-CoVwere infected in parallel with SARS-CoV
strain Frankfurt-1 and hCoV-EMC. The cells were infected with an MOI of 0.5 for 1 h, washed twice with phosphate-buffered saline (PBS), and supplemented
withmedium. At time points 0 and 40 h after infection, samples from supernatants were taken in order to extract viral RNA. Real-time reverse transcription-PCR
(RT-PCR) was used for absolute quantification of genome equivalents (GE) per ml of supernatant (2, 10). All experiments were performed in triplicate. hpi,
hours postinfection. (C) In order to block the ACE2 receptor, Vero cells were preincubated with 10g/ml of polyclonal goat anti-hACE2 for 1 h at 37°C. Half of
the antibody solution was stored, and cells were subsequently infected by adding viruses at anMOI of 0.01 for 30min at 4°C. The supernatant was discarded, and
mediumwith antibody solutionwas added. At time points 0 and 20 h postinfection, samples from supernatants (triplicate samples) were taken for quantification
by real-time RT-PCR. pAb, polyclonal antibody. (D) Virus-neutralizing activity of soluble recombinant hACE2 (rhACE2) was tested by preincubating in
triplicate different concentrations of rhACE2 (a kind gift from J. M. Penninger, Vienna, Austria) with 104 50% tissue culture infective dose (TCID50)/ml
hCoV-EMC (triangles) or 103 TCID50/ml SARS-CoV (squares) for 1 h. The mixture was added to Vero E6 cells for 1 h, after which cells were washed and fresh
medium was added. The infection was stopped after 8 h, and cells were visualized with a cross-reactive SARS-CoV serum followed by a goat anti-rabbit IgG
antibody conjugated to peroxidase and stained with 3-amino-9-ethylcarbazole (AEC) substrate.
hCoV-EMC Does Not Require the SARS-CoV Receptor
November/December 2012 Volume 3 Issue 6 e00515-12 ® mbio.asm.org 3
 o
n
 Septem
ber 12, 2019 by guest
http://m
bio.asm
.org/
D
ow
nloaded from
 
[Carollia]). Replication in porcine and primate cells suggests an
even broader tropism across mammals.
Large parts of the epidemiology and pathology of SARS were
related to its receptor tropism in humans (3, 11, 16). In a scenario
resembling that for avian influenza viruses, the anatomical posi-
tion of the receptor in the deep respiratory tract and the down-
regulation of its expression were postulated to aggravate the
course of disease in individuals while limiting the spread of disease
on the population level (24). While we are still uncertain of the
epidemiology of hCoV-EMC-related infections, the importance
of knowing its receptor in human cells is unquestionable (11).Our
data taken together suggest that hCoV-EMC does not rely on the
same receptor as SARS-CoV. Urgent further research is needed in
order to identify the cellular receptor for hCoV-EMC and deter-
mine its anatomical focus of replication.Our observations regard-
ing the cell culture tropism of this novel human virus raise an
intriguing perspective. We have shown here that cells from pri-
mates, pigs, as well as bats representing four families from both
chiropteran suborders, Yangochiroptera and Yinpterochiroptera,
retain susceptibility for the virus. This breadth of tropism is abso-
lutely unique among CoVs (1, 11, 12). For instance, only once
have researchers succeeded in culturing any CoV in bat-derived
cells, and these experiments required specifically generated bat cell
cultures combined with engineered, reporter gene-expressing vi-
rus (12). The broad replicative capability of hCoV-EMC suggests
that this new virus might utilize a receptor structure that bats,
primates, and pigs have in common. If that receptor were ex-
pressed inmucosal surfaces in those hosts, repeated acquisition by
humans would be conceivable, putting our current idea of a
“tight”molecular barrier against coronaviral cross-host transmis-
sion into perspective (11, 12). Interestingly, these data provide
strong support for the existence of “generalist” CoV, as recently
projected based on cell culture studies (12).
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hACE2-expressing transgenic Rousettus bat cell cultures (RoNi/7-hACE2)
were included. The cells were infected at an MOI of 0.5 for 1 h, washed twice
with PBS, and supplemented with medium. At time points 0 and 40 h postin-
fection, samples from supernatants were taken to extract viral RNA. Real-time
RT-PCR was performed as described for absolute quantification of GE. All
experiments were performed in triplicate. (C) A hACE2-blocking experiment
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